Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for epinephrine nasal spray

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 34 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Epinephrin (ATC-Code nach WHO: C01CA24) in der Darreichung Nasenspray

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The first submission deadline is fixed, and further deadlines are only available in a portal attachment not provided he...

Key participation documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') are referen...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing epinephrine in nasal spray form.
  • Open-House participation model with no individual negotiations and no exclusivity.
Pokaż pełne podsumowanie

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for epinephrine nasal spray (ATC C01CA24) in Germany. The contract is open to all interested pharmaceutical companies that meet and accept the stated participation conditions. No minimum purchase volume is guaranteed, no individual negotiations are conducted, and exclusivity is explicitly excluded. Participation documents must be obtained via DTVP after access approval, and submission is electronic via the portal communication function, not via the bidder tool. The notice is structured as a single lot, but the value is not stated.

Ryzyka

The first submission deadline is fixed, and further deadlines are only available in a portal attachment not provided he...

Key participation documents ('Anschreiben', 'Erläuterungen der Vertragsbedingungen', 'Einreichungsfristen') are referen...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of Section 4(18) AMG for the offered medicinal product.

Eligibility

  • The bidder must submit the completed declaration on the absence of exclusion grounds with the participation documents.

Administrative

  • The bidder must submit the declaration on Russia sanctions compliance using the specified form.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for epinephrine nasal spray

Single lot covering the conclusion of non-exclusive pharmaceutical rebate agreements under Section 130a(8) SGB V for epinephrine (WHO ATC C01CA24) in nasal spray form. The lot is an Open-House model, so any interested pharmaceutical company may participate if it meets and accepts the participation conditions. No exclusivity, no individual negotiations, and no guaranteed minimum purchase volume are stated. Performance/place of performance is Germany, with Dresden and the federal states of Saxony and Thuringia mentioned in the notice text.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Sep 2025 - Sep 2026

Kategoria

Pharmaceutical products

Termin

Deadline Sep 30, 2026

Szczegóły zamówienia

Data publikacji
31 Jul 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
504345-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3